Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
577
datasets available to search
ShareScore release 0.9.0
Dataset results
577 results for “Cholangiocarcinoma”
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
ClinicalTrials.gov study NCT02924376. IPD Sharing: YES. Countries: 12. Publications: 3.
Raw Data for the article: Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling
<p>Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive primary liver tumor, characterized by a range of different clinical manifestations and by increasing incidence and mortality rates even after curative treatment with radical resection. In recent years, growing attention has been devoted to this disease and some evidence supports liver transplantation (LT) as an appropriate treatment for intrahepatic cholangiocarcinoma; evolving work has also provided a framework for better understanding the genetic basis of this cancer. The aim of this study was to provide a clinical description of our series of patients complemented with Next-Generation Sequencing genomic profiling. From 1999 to 2021, 12 patients who underwent LT with either iCCA or a combined hepatocellular and cholangiocellular carcinoma (HCC-iCCA) were included in this study. Mutations were observed in gene activating signaling pathways known to be involved with iCCA tumorigenesis (KRAS/MAPK, P53, PI3K-Akt/mTOR, cAMP, WNT, epigenetic regulation and chromatin remodeling). Among several others, a strong association was observed between the Notch pathway and tumor size (point-biserial <em>rho<sub>pb</sub></em> = 0.93). Our results are suggestive of the benefit potentially derived from molecular analysis to improve our diagnostic capabilities and to devise new treatment protocols, and eventually ameliorate long-term survival of patients affected by iCCA or HCC-iCCA.</p>
Raw Data for the article: Liver transplantation for unresectable intrahepatic cholangiocarcinoma: an Italian experience
<p>Intrahepatic cholangiocarcinoma (iCCA) is an aggressive form of primary liver cancer treated exclusively with surgery.</p> <p>Its incidence in the western world is growing lately [<a href="https://link.springer.com/article/10.1007/s13304-021-01064-w#ref-CR1">1</a>] and the overall 5-year survival is poor due to late diagnosis, since patients rarely present a jaundice differently from patients affected by perihilar cholangiocarcinoma. Ideally liver resection and regional lymphadenectomy are the best treatments; however, these are unfortunately connotated by a 75% recurrence rate 5 years after surgery. Systemic chemotherapy offers a minimal response, as well as loco-regional therapy such as selective internal radiotherapy (SIRT), with a survival varying from 11 to 15 months between the two therapies</p>
Conventional, Functional and Radiomics Assessment for Intrahepatic Cholangiocarcinoma.
<p>I uploaded the images of the manuscript "Conventional, Functional and Radiomics Assessment for Intrahepatic Cholangiocarcinoma".</p>
Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma
<p>We uploaded the Figures of the manuscript: Granata V, Fusco R, Venanzio Setola S, Sandomenico F, Luisa Barretta M, Belli A, Palaia R, Tatangelo F, Grassi R, Izzo F, Petrillo A. Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma. Radiol Oncol. 2020 May 28;54(2):149-158. doi: 10.2478/raon-2020-0029. PMID: 32463393; PMCID: PMC7276649.</p> <p><strong>Abstract</strong></p> <p>Background. The aim of the study was to investigate the performance of the Liver Imaging Reporting and Data<br> System (LI-RADS) v2018 for combined hepatocellular-cholangiocarcinoma (cHCC-CCA) identifying the features that<br> allow an accurate characterization.<br> Patients and methods. Sixty-two patients (median age, 63 years; range, 38–80 years), with pre-surgical biopsy<br> diagnosis of hepatocellular carcinoma (HCC) that underwent hepatic resection, comprised our retrospective study.<br> All patients were subject to multidetector computed tomography (MDCT); 23 patients underwent to magnetic<br> resonance (MR) study. The radiologist reported the presence of the HCC by using LIRADS v2018 assessing major and<br> ancillary features.<br> Results. Final histological diagnosis was HCC for 51 patients and cHCC-CCA for 11 patients. The median nodule size<br> was 46.0 mm (range 10–190 mm). For cHCC-CCA the median size was 33.5 mm (range 20–80 mm), for true HCC the<br> median size was 47.5 mm (range 10–190 mm). According to LIRADS categories: 54 (87.1%) nodules as defined as LR-5,<br> 1 (1.6%) as LR-3, and 7 (11.3%) as LR-M. Thirty-nine nodules (63%) showed hyper-enhancement in arterial phase; among<br> them 4 were cHCC-CCA (36.4% of cHCC-CCA) and 35 (68.6%) true HCC. Forty-three nodules (69.3%) showed washout<br> appearance; 6 cHCC-CCAs (54.5% of cHCC-CCA) and 37 true HCC (72.5%) had this feature. Only two cHCCCCA<br> patients (18.2% of cHCC-CCA) showed capsule appearance. Five cHCC-CCA (71.4% of cHCC-CCA) showed<br> hyperintensity on T2-W sequences while two (28.6%) showed inhomogeneous signal in T2-W. All cHCC-CCA showed<br> restricted diffusion. Seven cHCC-CCA patients showed a progressive contrast enhancement and satellite nodules.<br> Conclusions. The presence of satellite nodules, hyperintense signal on T2-W, restricted diffusion, the absence of<br> capsule appearance in nodule that shows peripheral and progressive contrast enhancement are suggestive features<br> of cHCC-CCA.</p>
Intrahepatic cholangiocarcinoma and its Differential Diagnosis at MRI: How Radiologist Should Assess MR features.
<p>We uploaded the figures of the manuscript Intrahepatic cholangiocarcinoma and its Differential Diagnosis at MRI: How Radiologist Should Assess MR features submitted on Radiologia Medica.</p> <p> </p> <p><strong>Figure Legend</strong>:</p> <p>Figure 1: mass-forming ICC; the lesion shows a targetoid appearance, with central fibrous stroma in T2-W sequence (A, arrow), DWI (B: b800s/mm<sup>2</sup>, arrow) and ADC map (C, arrow). During contrast study (arterial phase (D, arrow), portal (E, arrow), transitional (F, arrow), the lesion shows a progressive contrast enhancement.</p> <p>Figure 2: mass-forming ICC on left lobe, with diffuse metastases. The lesions show in T2-W sequences (A, B and C, arrows) targetoid appearance with central fibrosis in ICC and necrosis in metastases; TA is also present in DWI (D: b800 s/mm<sup>2</sup>, arrow) and ADC map (E, arrow). In arterial phase (F, arrow) the lesions show rim APHE with progressive contrast enhancement during portal phase (G, arrow).</p> <p>Figure 3: periductal infiltrating ICC; in T2-W sequence the lesion shows hypeintense SI (A, arrow); in DWI (B, arrow) and ADC map (C, arrow), biliary stent causes a dysomogeneous SI. During arterial (D, arrow) and portal phase (E, arrow) the lesion shows a progressive contrast enhancement.</p> <p>Figure 4: intraductal growing ICC. In T2-W sequence (A, arrow) the lesion shows hyperintense SI, with biliary dilatation and restricted signal in DWI (B, arrow) and ADC map (C, arrow) during arterial (D, arrow), portal (E, arrow) and late phase (F, arrow) the lesion shows a progressive contrast enhancement.</p> <p>Figure 5: mCRC patient. The lesions show targetoid appearance in T2-W sequence (A, arrow), DWI (B, arrow) and ADC map (C, arrow). In arterial phase (D, arrow) the lesions show rim APHE and hypointense SI in portal (E and F, arrows) phase. In F the arrow shows a pheripheral rim enhancement.</p> <p>Figure 6: Peribiliary metastases in pancreatic cancer patient. In T2-W the lesion shows hyperintense SI (A, arrow), with restricted diffusion (B, arrow) and iso-hypointense SI in ADC map (C, arrow). During arterial (D, arrow), portal (E, arrow) and transitional (F, arrow) phase the lesion shows a progressive contrast enhancement.</p> <p>Figure 7: HCC patient. In T2-W the lesion shows iso-hypeintense SI (A, arrow), with hypointense SI in T1-W (B: in phase; C: out phase, arrows). During arterial phase the lesion shows APHE (D, arrow), with washout appearance (E, arrow) and capsule appearance (F, arrow). The Diffusion is restricted (G: b500 s/mm<sup>2</sup>; H: b800 s/mm<sup>2</sup> and I: ADC map, arrows).</p> <p>Figure 8: cHCC-ICC patient. The lesion shows targetoid appearance in T2-W (A, arrow) and T1-w sequences (B: in phase and C: out of phase, arrows). During contrast study, the lesion shows progressive contrast enhancement (D: arterial phase; E: portal phase and F: equilibrium phase, arrows). In DWI sequences, the lesion shows targetoid appearance (G= b50 s/mm<sup>2</sup>; H: b800s/mm<sup>2</sup> and I: ADC map, arrows)</p> <p>Figure 9: hepatic hemangioma; in T2 (A, arrow) sequence the lesion shows hyperintense SI, with progressive contrast enhancement in arterial (B, arrow), portal (C, arrow) and equilibrium (D: coronal plane, arrow) phase.</p>
Proteogenomic Characterization of Cholangiocarcinoma
<p>supplemental table of Integrated Proteogenomic Characterization of Cholangiocarcinoma Associated with Clinical Outcomes</p>
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT04251715. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
ClinicalTrials.gov study NCT04891289. IPD Sharing: YES. Countries: 2. Publications: 0.
A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
ClinicalTrials.gov study NCT03250273. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
ClinicalTrials.gov study NCT02989857. IPD Sharing: YES. Countries: 6. Publications: 4.
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT02807181. IPD Sharing: NO. Countries: 8. Publications: 0.
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
ClinicalTrials.gov study NCT00033540. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
ClinicalTrials.gov study NCT03801915. IPD Sharing: YES. Countries: 1. Publications: 1.
Codman Catheter/Synchromed Pump Hepatic Artery Chemotherapy for Unresectable Colorectal Metastases/Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT04276090. IPD Sharing: NO. Countries: 1. Publications: 1.
M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)
ClinicalTrials.gov study NCT03833661. IPD Sharing: YES. Countries: 9. Publications: 3.
Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma
ClinicalTrials.gov study NCT00721175. IPD Sharing: Not stated. Countries: 1. Publications: 4.
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors
ClinicalTrials.gov study NCT04034238. IPD Sharing: YES. Countries: 1. Publications: 1.
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
ClinicalTrials.gov study NCT01862315. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT03230318. IPD Sharing: NO. Countries: 11. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.